ARTICLE | Company News

Servier, Taiho sales and marketing update

August 1, 2016 7:00 AM UTC

The U.K.’s NICE issued final draft guidance recommending Lonsurf trifluridine/tipiracil from Servier to treat metastatic colorectal cancer (mCRC) in patients previously treated with or who are not candidates for some chemotherapies, anti-VEGF agents and anti- EGFR therapies. The recommendation is contingent on Servier providing Lonsurf at an undisclosed discount through a patient access scheme. The recommended dose is twice-daily 35 mg/m 2 per dose given on days 1 to 5 and 8 to 12 of each 28-day cycle. The average cost of Lonsurf per cycle of treatment is L1,625 ($2,132) with the discounted price including the patient access scheme. NICE said the incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained is L49,392 ($64,817).

Lonsurf is an oral combination of trifluridine (FTD), an antineoplastic nucleoside analog, and tipiracil, an inhibitor of the FTD-degrading enzyme thymidine phosphorylase. ...